Identification of Nine New *RAI1*-Truncating Mutations in Smith-Magenis Syndrome Patients without 17p11.2 Deletions

C. Dubourg^{a,b} F. Bonnet-Brilhault^d A. Toutain^e C. Mignot^{f,g} A. Jacquette^f
A. Dieuxⁱ M. Gérard^j M.-P. Beaumont-Epinette^a S. Julia^k B. Isidor^l M. Rossi^m
S. Odent^{b,c} C. Bendavid^b C. Barthélémy^d A. Verloes^h V. David^{a,b}

^aLaboratoire de Génétique Moléculaire, CHU Pontchaillou, ^bCNRS UMR 6290, IFR140, Université de Rennes 1, and
^cService de Génétique Médicale, CHU Hôpital Sud, Rennes, Services de ^dPsychiatrie and ^eGénétique, CHRU Bretonneau,
Tours, ^fService de Génétique Clinique, CHU La Pitié Salpêtrière, ^gService de Neuropédiatrie, APHP, Hôpital Armand
Trousseau, and ^hService de Génétique Clinique, CHU Robert Debré, Paris, ⁱService de Génétique Clinique, CHU, Lille,
^jService de Génétique, CHR Clémenceau, Caen, ^kService de Génétique Médicale, CHU Purpan, Toulouse, ^lService de
Génétique Médicale, CHU, Nantes, and ^mService de Génétique Clinique, CHU, Lyon-Bron, France

Key Words

Mutation · 17p11.2 · *RAI1* · Smith-Magenis syndrome

Abstract

Smith-Magenis syndrome (SMS) is an intellectual disability syndrome with sleep disturbance, self-injurious behaviors and dysmorphic features. It is estimated to occur in 1/25,000 births, and in 90% of cases it is associated with interstitial deletions of chromosome 17p11.2. *RAI1* (retinoic acid induced 1; OMIM 607642) mutations are the second most frequent molecular etiology, with this gene being located in the SMS locus at 17p11.2. Here, we report 9 new *RAI1*-truncating mutations in nonrelated individuals referred for molecular analysis due to a possible SMS diagnosis. None of these patients carried a 17p11.2 deletion. The 9 mutations include 2 nonsense mutations and 7 heterozygous frame-shift mutations leading to protein truncation. All mutations map in exon 3 of *RAI1* which codes for more than 98% of the protein. *RAI1* regulates gene transcription, and its targets are themselves involved in transcriptional regulation, cell growth and cell cycle regulation, bone and skeletal development, lipid and glucide metabolisms, neurological develop-

ment, behavioral functions, and circadian activity. We report the clinical features of the patients carrying these deleterious mutations in comparison with those of patients carrying 17p11.2 deletions.

© 2014 S. Karger AG, Basel

Smith-Magenis syndrome (SMS; MIM 182290) involves multiple congenital anomalies and intellectual disability usually associated with an interstitial deletion of chromosome 17p11.2 [Smith et al., 1986; Greenberg et al., 1996; Dykens and Smith, 1998; Potocki et al., 2000; De Leersnyder et al., 2001; Edelman et al., 2007; Gropman et al., 2007; Elsea and Girirajan, 2008]. The common features include behavioral abnormalities with sleep disturbances, self-injurious and/or aggressive behavior, particular craniofacial and skeletal anomalies, and speech delay. The facial appearance is usually characterized by a broad square-shaped face, a tented (inverted V-shaped) upper lip with downturned corners of the mouth and upslanting palpebral fissures. Obesity is frequent.

The incidence of this syndrome has been estimated to be 1 in 25,000 births [Greenberg et al., 1991]. About 90%

Table 1. *RAI1* PCR primers and conditions

Exon	Forward primer (5'→3')	Reverse primer (5'→3')	Product size, bp	Annealing temp., °C
2	GGGGCTGCTAAGAAGCAAAC	CGCCGAAAACACAAAGCTC	306	56
3.1	GGTGGGTGGGAGGGTGCTTT	TGCTGTCCTGGACGCCGTAG	489	57
3.2	AGTACCACCGAGGCAGCA	TCGGTGCTGTGCAACTCTTA	498	57
3.3	CAGGGTACCCACTTTCCTCA	AGTTCTCCAGGTTTGCCATC	496	57
3.4	CAGGAAACCTCCATTACCA	GCTGGCTTTTATGCTGCTCT	541	57
3.5	CTCCCTGAGAACCTGCTGTC	CCACGAACTTGGAGAAGCTG	502	57
3.6	AGTCCGTGTCCACCTGTTCT	GTCCGGGAAACAGTCAAAAG	542	57
3.7	TCTCGCTGGAGAACCACAG	CACCTGCCTCCTCCTTCAC	549	57
3.8	CTCAGATGGCATCAGCAAAG	TCAAACCAGCTCTGGACCTT	504	57
3.9	CACTCATCTGCACCAAGGAG	GCCGTGAGAGAACGAGTACA	499	57
3.10	AAGACCTATTGCTCCCTGAA	TTGTGCGAGGAGCTTCTTGGT	475	57
3.11	GAGACAGACTCACCCAGCAC	CAGCACCTTGGTCTTCATGG	570	57
3.12	AGTGGCAATGGGGGAGAT	GCCTCGGTTTTGAAACAGTC	530	57
3.13	GGCCTCTCCTGGTAATCCTC	TGTTTCTGTGCCCTTGTCTG	525	57
3.14	GGCCAGTGAGGACAACCTCTG	AGGAGAACGAGGACGAGGAT	467	57
3.15	GACGCGTTCACCACCATA	CATCACAGCAGTAGCAGCTC	550	57
3.16	ACACTGCCTCCCCAAAAG	GTCCCTTGGAAACCCACAC	487	57
4	CCAGCCTGTAAAGCTTGAGG	CTCCAATGCCCTCCTGTTC	197	56
5	TCCTGGCTGCAGACAAAAC	GGGGACTGTGAAGGAGGTG	207	56
6.1	ACTGTGAAGTCCGAGGTCGT	GAAAGTGTCCCCAGGACAAA	420	58
6.2	GGGAGGAAAACCCGTTCC	AGAGGCCAAAGGGTGTCC	549	58
6.3	GGAGCCTTTGGAACAAACC	GTCGCGGTAGCCCCCTTAC	489	58
6.4	GGAACATGCTCGCTTCTCC	CAGCTGAATCTGGTCGGAAT	545	62

of SMS patients present a heterozygous interstitial deletion of chromosome 17p11.2: most (70% of SMS patients) have a common ~3.7-Mb deletion [Greenberg et al., 1991; Juyal et al., 1996; Gropman et al., 2007] mediated by non-allelic homologous recombination (NAHR) [Chen et al., 1997; Park et al., 2002]; about 20% of SMS patients harbor atypical deletions of ~1.5–9 Mb mediated by an end-joining mechanism [Trask et al., 1996; Bi et al., 2002; Stankiewicz et al., 2003; Vlangos et al., 2003; Shaw and Lupski, 2005]. More recently, point mutations in the *RAI1* (retinoic acid induced 1) gene have been identified in less than 10% of SMS patients [Slager et al., 2003; Bi et al., 2004, 2006; Girirajan et al., 2005, 2006; Vilboux et al., 2011; Vieira et al., 2012]. This gene maps in the SMS critical region [Bi et al., 2002; Vlangos et al., 2003]. About 36 mutations have been described in *RAI1* to date, and more than 50% of them are truncating mutations; the deleterious role of the missense mutations is not yet clearly established. The *RAI1* gene encodes a potential transcriptional regulator and consists of 6 exons that span over 120 kb; the third exon contains more than 98% of the coding sequence [Bi et al., 2004, 2005]. The *RAI1* protein contains polyglutamine and polyserine tracts, bipartite nuclear localization

signals and a plant homeo/zinc finger domain at the C-terminus [Toulouse et al., 2003]. Murine *Rai1* (originally reported as *GT1*) is upregulated by retinoic acid treatment in mouse embryonal carcinoma cells concomitantly with neuronal differentiation [Imai et al., 1995].

We report 9 new *RAI1*-truncating mutations in SMS patients without 17p11.2 deletions, describe associated phenotypes and compare our results with published findings.

Methods

Patients and Samples

Patients presenting with clinical symptoms of SMS, but without a 17p11.2 deletion, were referred from various clinical genetic centers in France through the network of the reference centers for developmental anomalies and malformation syndromes. All patient samples were collected after obtaining informed consent according to the guidelines of the relevant institutional review boards.

PCR and Sequencing

Patient DNA was amplified by PCR with overlapping primers covering exons 2–6 of the *RAI1* gene and using the conditions de-

Fig. 1. Photographs of faces and extremities of some patients carrying an *RAI1* mutation.

scribed in table 1. PCR products were purified and then analyzed by direct sequencing using the BigDye terminator v3.1 Cycle Sequencing Kit and the ABI Prism 3130 Genetic Analyzer (all from Applied Biosystems, Carlsbad, Calif., USA). The gene mutation nomenclature used in this article follows the recommendations of den Dunnen and Antonarakis [2001]. When material from the parents was available, a family study was performed to prove that the mutation occurred *de novo*.

Results

Patients presenting with clinical symptoms of SMS (fig. 1; table 2), but without 17p11.2 deletion, were referred to us, and we screened them for mutations in the *RAI1* gene. We report here 9 novel mutations, all in exon 3 of the gene (fig. 2), that support a diagnosis of SMS in these cases.

RNS78

RNS78 is the third child of healthy unrelated parents. Pregnancy was normal, but she had major reflux problems in the neonatal period. She developed overgrowth at ~5 months of age and is bulimic. In addition to facial dysmorphism and extremity anomalies, she suffers significant sleep disturbance including early awakening, early sleeping in the evening and multiple napping. She presents learning difficulties and an oppositional behavior with aggressiveness; she is, however, sociable.

Laboratory findings included a normal karyotype and normal FISH for del(17)(p11.2). RNS78 has a heterozygous cytosine to thymine transition at nucleotide 238

(c.238C>T) in the *RAI1* gene, producing a nonsense substitution (p.Arg80*): the reading frame is interrupted by a premature stop codon.

RNS59

RNS59 presents with developmental delay, significant language retardation, behavioral problems, and major sleeping disturbance. He spoke his first word at the age of 3 years and his first sentence at 5. He displays impulsiveness and self- and heteroaggressiveness. A study of the rhythm of melatonin release gave a flat trace with an inversion of the circadian rhythm as early as at the age of 15 months. This patient is awake for long periods through the night and frequently naps during the day, with a shorter than usual total sleep time.

Pharmacogenetic analysis of cytochrome P450 2D6 revealed an ultrarapid metabolism.

RNS59 carries a duplication of a single adenine in exon 3 at nucleotide position 3,386 on one *RAI1* allele (c.3386dupA). This duplication results in a frameshift starting at amino acid 1130, leading to misincorporation of 35 amino acids and a downstream stop codon. Neither parent carried this p.Glu1130Glyfs*36 in DNA.

RNS101

RNS101 is the second son of healthy unrelated parents. Pregnancy was normal. Early problems included frequent bronchiolitis. Growth was steady over the 2 first years and then tended to obesity. He displays developmental delay, significant language delay, behavioral problems includ-

Table 2. Clinical characteristics of patients with *RAI1* mutations

	RNS78	RNS59	RNS101	RNS103	RNS86	RNS105	RNS131	RNS165	RNS208
<i>RAI1</i> mutation	c.238C>T p.Arg80*	c.3386dupA p.Glu1130Glyfs*36	c.2869_2870insGG p.Asp957Glyfs*108	c.518_519insG p.Gln174Profs*64	c.2643delC p.Glu882Serfs*68	c.1297C>T p.Gln433*	c.2763_2779dup17 p.Leu927Glnfs*29	c.2396dupC p.Gly800Trpfs*36	c.2836_2837delCT p.Leu946Valfs*7
Age at time of report	8 years	19 years	14 years	29 years	7.5 years	5.5 years	6 years	9 years	9 years
Sex	f	m	m	m	m	m	m	m	f
Growth measures, percentiles									
weight	92 nd	73 rd	>97 th	>97 th	95 th	90 th	75 th	90 th	55 th
height	50 th	25 th	75 th	20 th	70 th	12 th	10 th	24 th	3 rd
HC	80 th	<3 rd	90 th	95 th	10 th	50 th	80 th	30 th	30 th
Overweight	+	+	+	+	+	+	+	+	+
Developmental delay	+	+	+	+	+	+	+	+	+
Facial dysmorphism	egg-shaped face, horizontal eyebrows, synophrys, hypertelorism, short and upturned nose	square face, large mouth, thick lips with tented upper lip and everted lower lip	square face, high forehead, short philtrum, thick lips with tented upper lip and everted lower lip	tented upper lip, short philtrum, uplifted ear lobes	upslanting palpebral fissures, anteverted nostrils, long philtrum, tented upper lip	short philtrum	tented upper lip, brachycephaly	synophrys, short philtrum	anteverted nostrils, long philtrum, tented upper lip
Short extremities	+	+	+	+	+	+	-	+	+
	bilateral clinodactyly of the fifth finger								bilateral clinodactyly of the fifth finger
Sleep disturbance	+	+	+	+	+	+	+	+	+
	early morning awakening (before 5 a.m.) and early sleeping in the evening	inverted circadian rhythm for melatonin	moderate	early morning awakening (5:30 a.m.)	early morning awakening (4 or 5 a.m.)	early morning awakening and the evening	early morning awakening (5 a.m.) and inverted circadian rhythm for melatonin	early morning awakening (5 a.m.) and inverted circadian rhythm for melatonin	early morning awakening (4 a.m.)
Behavioral problems	+	+	+	+	+	+	+	+	+
	aggressiveness, overeating	impulsiveness, aggressiveness, self-injurious behavior	rage attacks, hyperactivity, self-injurious behavior, head banging, aggressiveness, overeating (compulsive behavior)	self-injurious behavior	self-injurious behavior, aggressiveness		overeating		impulsiveness, aggressiveness, overeating
HC = Head circumference; + = present; - = absent.

Fig. 2. Diagram showing the structure of *RAI1* in the genome with 6 exons and summarizing truncating mutations associated with SMS. All truncating mutations reported to date are indicated, including those described in this study¹ and in Slager et al. [2003]², Bi et al. [2004]³, Girirajan et al. [2005]⁴, Girirajan et al. [2006]⁵, Bi et al. [2006]⁶, Truong et al. [2010]⁷, and Vilboux et al. [2011]⁸:

4 nonsense (indicated by lightning flashes) and 17 frameshift (indicated by arrows) mutations. The numbering of nucleotides is based on GenBank NM_030665.3. The filled boxes represent the *RAI1* coding region, and the hollow boxes represent noncoding regions.

ing fits of anger, and moderate sleeping disturbance with night awakenings. His hands are short, and his feet are broad. He presents joint hyperlaxity.

Laboratory findings included a normal karyotype, negative fragile X and subtelomeric microarrangement results, normal FISH for 17p11.2 deletion, and normal pangenomic array CGH. RNS101 has a heterozygous insertion of 2 guanines after nucleotide position 2,869 (c.2869_2870insGG) in the *RAI1* gene, resulting in a frameshift starting at amino acid residue 957, a misincorporation of 107 amino acids and a downstream stop codon (p.Asp957Glyfs*108).

RNS103

RNS103 is a 29-year-old man presenting syndromic obesity. There is no family history of mental handicap or congenital malformations, and the pregnancy was normal. Birth weight was 3,340 g, and there were no feeding difficulties during the neonatal period. He presented subsequently with developmental delay including walking and language delay, but he learned to read and write and now works in an 'Etablissement et Service d'Aide par le Travail' (French working environment adapted to those with difficulties). Behavioral problems include significant sleep disturbance with frequently interrupted sleeping and early waking (5:30 a.m.) and self-aggressiveness.

He has short fingers and toes and one 'café au lait' spot on the trunk.

Laboratory findings include a normal karyotype, normal methylation of the chromosome 15, negative test re-

sults for fragile X, normal FISH for del(17)(p11.2), and no deleterious microarrangement observed on array CGH.

RNS103 carries an insertion of one guanine after nucleotide 518 on one allele of *RAI1* (c.518_519insG). This insertion results in a frameshift starting at amino acid 174, leading to misincorporation of 63 amino acids and a downstream stop codon (p.Gln174Profs*64).

RNS86

RNS86 presents developmental delay and major behavioral problems including self- and heteroaggressiveness. He has significant sleep disturbance and facial dysmorphisms as well as astigmatism and hypermetropia. His hands are short with a transverse palmar crease on the left hand, and he presents hyperlaxity. Over the past 2 years, his weight has increased substantially.

Metabolic balance, fragile X analysis, MRI, high resolution karyotype, and pangenomic array CGH did not reveal any anomaly.

RNS86 carries a deletion of a single cytosine in exon 3 at nucleotide 2,643 on one allele of *RAI1* (c.2643delC). This deletion results in a frameshift starting at amino acid 882, leading to misincorporation of 67 amino acids and a downstream stop codon (p.Glu882Serfs*68).

RNS105

RNS105 presents with moderate developmental delay and significant language retardation. He could walk at 16 months. He displays a characteristic sleep disturbance including early sleeping in the evening, early waking and

frequent napping; however, there is no aggressive behavior. He has shawl scrotum and shows hyperlaxity with bilateral sloped feet.

Additional laboratory findings include a normal karyotype, a normal pangenomic array CGH excluding an interstitial deletion of chromosome 17p11.2 and negative fragile X and *FGD1* studies. RNS105 has a heterozygous cytosine to thymine transition at nucleotide 1,297 in the *RAI1* gene, producing a nonsense substitution (p.Gln433*): the reading frame is interrupted by a premature stop codon.

RNS131

RNS131 presents developmental delay, hypotonia, dysmorphism, macrocephaly, behavioral problems, and overweight. He could walk at 21 months. His BMI increased excessively until he was 3 years old, and then, it declined following strict diet control. Sleep disturbances began in the second year of life with multiple waking during the night. He presents moderate hyperlaxity. He is the first of 2 children. His younger sister has a paternally inherited microrearrangement of the X chromosome, but RNS131 did not inherit this familial rearrangement.

Laboratory findings for this boy include a normal karyotype, negative fragile X and Prader-Willi studies, normal FISH for del(17)(p11.2), and normal pangenomic array CGH. The metabolic findings are normal. Sequencing of exon 3 of the *RAI1* gene revealed a 17-bp duplication (c.2763_2779dup17) that results in a frameshift starting at amino acid 927 and leading to a downstream stop codon (p.Leu927Glnfs*29).

RNS165

RNS165 presents with sleep disturbances and inversion of the circadian rhythm for melatonin, developmental delay, behavioral problems, facial dysmorphism, astigmatism, hypermetropia, and brachydactyly.

RNS165 has a duplication of one cytosine (c.2396dupC) on one allele of *RAI1* leading to a frameshift and a downstream stop codon at position 836 (p.Gly800Trpfs*36).

RNS208

RNS208 is the first child of healthy unrelated parents. Pregnancy was normal. She walked at the age of one year and spoke her first words at only 2. She displays impulsiveness and aggressiveness and always awakes early.

RAI1 sequencing revealed a 2-bp deletion (c.2836_2837delCT) that results in a frameshift starting at amino acid 946 and ending by a premature stop codon (p.Leu946Valfs*7).

Discussion

We report 9 patients with deleterious mutations in the *RAI1* gene, all displaying similar features consistent with a diagnosis of SMS; in all 9 cases, a 17p11.2 deletion was excluded by FISH, MLPA or array CGH. Clinical symptoms observed in these patients correlate with previous reports of *RAI1*-mutated patients [Slager et al., 2003; Bi et al., 2004, 2006; Girirajan et al., 2005, 2006; Vilboux et al., 2011]. No immunologic, cardiovascular or renal features were noted.

The *RAI1* gene, located on chromosome 17p11.2, comprises 6 exons generating a 7.6-kb mRNA [Toulouse et al., 2003]. This mRNA (GenBank NM_030665.3) contains a 470-bp 5'UTR (the first 2 exons and the 16 first nucleotides of exon 3) and a 1,452-bp 3'UTR (corresponding to the sixth exon). *RAI1* encodes a nuclear protein containing a single zinc finger plant homeo domain, which is also present in the trithorax family of chromatin-remodeling transcriptional regulators, implicating *RAI1* in the regulation of gene transcription [Bi et al., 2005, 2006]. *RAI1* has 2 putative bipartite nuclear localization signals. Functional and cellular analyses of 5 mutated forms of the human *RAI1* protein indicate that the N-terminal half of the protein has transcription factor activity (within the first 1,034 amino acids), and the C-terminal half is responsible for its transportation into the nucleus [Carmona-Mora et al., 2010].

All previously reported mutations map in exon 3 (5,581 bp) which codes for more than 98% of the protein. The mutations are scattered all along this third exon, and there is no evidence for a hot spot. We report 7 frameshift and 2 nonsense mutations, also all in the third exon (fig. 2). The nonsense and frameshift mutations are predicted to result in truncated proteins due to direct or downstream stop codons.

Indeed, most deleterious mutations identified in the *RAI1* gene lead to the production of truncated proteins. These mutations are unique, dominant and, in cases for which familial analysis was possible, de novo.

Antonarakis et al. [2000] suggested that single-base deletions causing frameshifts occurred in runs of identical bases, and Truong et al. [2010] postulated a preferential frameshift mutation hotspot in the *RAI1* gene in a heptameric C-tract (c.3097_3103). We did not detect any mutation at this site in *RAI1*; however, the c.2643delC alteration predicted to cause a p.Glu882Serfs*68 frameshift mutation occurred in a mononucleotide repeat of 4 cytosines. The c.2869_2870insGG frameshift mutation maps immediately downstream from a guanine and the

c.3386dupA from 2 adenines. These mutations may therefore have been the consequence of slipped mispairing [Streisinger et al., 1966; Tautz and Schlötterer, 1994]. It is noticeable, however, that guanine and cytosine runs have a higher mutation rate than adenine and thymine runs [Sagher et al., 1999; Boyer et al., 2002].

A polymorphic CAG repeat, starting from *RAI1* nucleotide position 832, encodes a polyglutamine stretch in the N-terminus of the protein. Alleles of 10–16 glutamines have been described in the general population [Bi et al., 2006]. In our cohort of 80 patients with the clinical symptoms of SMS, but without 17p11.2 deletion, 44% have 14 glutamines, 52% 13 glutamines, 2% 15 glutamines, 1% 11 glutamines, and 1% 10 glutamines. Five of our 9 patients with an identified *RAI1* mutation have 14 glutamines and 4 have 13 glutamines. No significant association has been reported between the length of CAG repeats and the SMS phenotype when the number of CAG trinucleotides remains in the range from 10 to 16 repeats. However, large CAG repeats could influence expressivity and severity of the SMS phenotype in patients who present a *RAI1* mutation on the second allele [Seranski et al., 2001; Bi et al., 2006].

Downstream targets of the transcription factor *RAI1* are involved in transcriptional regulation (*RXRβ*, *ZNF236*, *ZIC1*, *RUNX1T1*, *AKR7A3*, *FBLN1*), cellular growth and cell cycle regulation (*SPTBN1*, *POLDIP3*, *PPP1R14D*, *GLI3*, *KMT2A*, *ADD3*), bone and skeletal development (*PSTPIP2*, *ANKH*), lipid biosynthesis and cholesterol metabolism (*LIPE*, *HMGCS1*, *INSIG1*), neurological development (*ZIC1*, *PSEN2*, *RXRβ*, *CLN8*, *SMA4*, *NF1*, *KMT2A*), behavioral functions (*SCN12A*), circadian activity (*NR1D2*, *PER2*, *PER3*, *CRY1*, *ARNTL*), and insulin and glucose regulation (*INSIG1*, *PIK3R1*, *ZNF236*, *LIPE*) [Girirajan et al., 2009]. Interestingly, each of these biological functions is dysregulated in SMS patients: these patients present with, in particular, obesity, altered circadian rhythm, hypercholesterolemia, hypertriglyceridemia, intellectual disability, and abnormal behavior.

The role of *RAI1* haploinsufficiency in the complex pathogenicity of obesity on the one hand and of sleep disturbances on the other hand has been demonstrated. First, expression analysis reveals that *Bdnf* (brain-derived neurotrophic factor), a gene associated with hyperphagia and obesity, is downregulated in the hypothalamus of *Rai1*^{+/-} mice, and reporter studies show that *RAI1* directly regulates the expression of *BDNF* [Burns et al., 2010]. Second, haploinsufficiency of *RAI1* in SMS fibroblasts and in the mouse hypothalamus, respectively, results in the transcriptional dysregulation of the circadian clock and causes altered expression and regulation of multiple circadian genes, including *PER2*, *PER3*, *CRY1*, and *ARNTL* [Williams et al., 2012]. This study suggests that a heterozygous mutation of *RAI1* alters the circadian rhythm and results in an abnormal sleep-wake cycle, which can contribute to an abnormal feeding pattern and dependent cognitive performance.

In summary, haploinsufficiency of *RAI1* is the main responsible for the neurological, behavioral and craniofacial features of SMS, even if other genes or genetic background may play a role in modulating these features. Consistent with patients previously described with *RAI1* mutations, the patients we report differ from patients carrying a 17p11.2 deletion: *RAI1* mutations are associated with less substantial motor delay, greater inclination to overweight, no hearing loss, no seizures, and no associated systemic malformations. Therefore, one or more other genes in the 17p11.2 region are probably involved in these variable associated features more frequently observed in SMS patients with deletions [Gropman et al., 2007]. More research is required for a better understanding of the role of additional genes and to consider new treatment strategies.

Acknowledgements

We thank all clinicians who referred SMS cases and all families for giving their consent for this study.

References

- Antonarakis SE, Krawczak M, Cooper DN: Disease-causing mutations in the human genome. *Eur J Pediatr* 159 Suppl 3:S173–S178 (2000).
- Bi W, Yan J, Stankiewicz P, Park SS, Walz K, et al: Genes in a refined Smith-Magenis syndrome critical deletion interval on chromosome 17p11.2 and the syntenic region of the mouse. *Genome Res* 12:713–728 (2002).
- Bi W, Saifi GM, Shaw CJ, Walz K, Fonseca P, et al: Mutations of *RAI1*, a PHD-containing protein, in nondeletion patients with Smith-Magenis syndrome. *Hum Genet* 115:515–524 (2004).
- Bi W, Ohyama T, Nakamura H, Yan J, Visvathan J, et al: Inactivation of *Rai1* in mice recapitulates phenotypes observed in chromosome engineered mouse models for Smith-Magenis syndrome. *Hum Mol Genet* 14: 983–995 (2005).

- Bi W, Saifi GM, Girirajan S, Shi X, Szomju B, et al: *RAI1* point mutations, CAG repeat variation, and SNP analysis in non-deletion Smith-Magenis syndrome. *Am J Med Genet A* 140: 2454–2463 (2006).
- Boyer JC, Yamada NA, Roques CN, Hatch SB, Riess K, Farber RA: Sequence dependent instability of mononucleotide microsatellites in cultured mismatch repair proficient and deficient mammalian cells. *Hum Mol Genet* 11: 707–713 (2002).
- Burns B, Schmidt K, Williams SR, Kim S, Girirajan S, Elsea SH: *Rai1* haploinsufficiency causes reduced *Bdnf* expression resulting in hyperphagia, obesity and altered fat distribution in mice and humans with no evidence of metabolic syndrome. *Hum Mol Genet* 19: 4026–4042 (2010).
- Carmona-Mora P, Encina CA, Canales CP, Cao L, Molina J, et al: Functional and cellular characterization of human Retinoic Acid Induced 1 (*RAI1*) mutations associated with Smith-Magenis Syndrome. *BMC Mol Biol* 11:63 (2010).
- Chen KS, Manian P, Koeuth T, Potocki L, Zhao Q, et al: Homologous recombination of a flanking repeat gene cluster is a mechanism for a common contiguous gene deletion syndrome. *Nat Genet* 17:154–163 (1997).
- De Leersnyder H, De Blois MC, Claustrat B, Romana S, Albrecht U, et al: Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome. *J Pediatr* 139:111–116 (2001).
- den Dunnen JT, Antonarakis SE: Nomenclature for the description of human sequence variations. *Hum Genet* 109:121–124 (2001).
- Dykens EM, Smith AC: Distinctiveness and correlates of maladaptive behaviour in children and adolescents with Smith-Magenis syndrome. *J Intellect Disabil Res* 42:481–489 (1998).
- Edelman EA, Girirajan S, Finucane B, Patel PI, Lupski JR, et al: Gender, genotype, and phenotype differences in Smith-Magenis syndrome: a meta-analysis of 105 cases. *Clin Genet* 71:540–550 (2007).
- Elsea SH, Girirajan S: Smith-Magenis syndrome. *Eur J Hum Genet* 16:412–421 (2008).
- Girirajan S, Elsas LJ 2nd, Devriendt K, Elsea SH: *RAI1* variations in Smith-Magenis syndrome patients without 17p11.2 deletions. *J Med Genet* 42:820–828 (2005).
- Girirajan S, Vlangos CN, Szomju BB, Edelman E, Trevors CD, et al: Genotype-phenotype correlation in Smith-Magenis syndrome: evidence that multiple genes in 17p11.2 contribute to the clinical spectrum. *Genet Med* 8: 417–427 (2006).
- Girirajan S, Truong HT, Blanchard CL, Elsea SH: A functional network module for Smith-Magenis syndrome. *Clin Genet* 75:364–374 (2009).
- Greenberg F, Guzzetta V, Montes de Oca-Luna R, Magenis RE, Smith AC, et al: Molecular analysis of the Smith-Magenis syndrome: a possible contiguous-gene syndrome associated with del(17)(p11.2). *Am J Hum Genet* 49: 1207–1218 (1991).
- Greenberg F, Lewis RA, Potocki L, Glaze D, Parke J, et al: Multi-disciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2). *Am J Med Genet* 62:247–254 (1996).
- Gropman AL, Elsea S, Duncan WC Jr, Smith AC: New developments in Smith-Magenis syndrome (del17p11.2). *Curr Opin Neurol* 20: 125–134 (2007).
- Imai Y, Suzuki Y, Matsui T, Tohyama M, Wanaka A, Takagi T: Cloning of a retinoic acid-induced gene, *GT1*, in the embryonal carcinoma cell line P19: neuron-specific expression in the mouse brain. *Brain Res Mol Brain Res* 31:1–9 (1995).
- Juyal RC, Figueroa LE, Hauge X, Elsea SH, Lupski JR, et al: Molecular analyses of 17p11.2 deletions in 62 Smith-Magenis syndrome patients. *Am J Hum Genet* 58:998–1007 (1996).
- Park SS, Stankiewicz P, Bi W, Shaw C, Lehoczyk J, et al: Structure and evolution of the Smith-Magenis syndrome repeat gene clusters, SMS-REPs. *Genome Res* 12:729–738 (2002).
- Potocki L, Glaze D, Tan DX, Park SS, Kashork CD, et al: Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. *J Med Genet* 37:428–433 (2000).
- Sagher D, Hsu A, Strauss B: Stabilization of the intermediate in frameshift mutation. *Mutat Res* 423:73–77 (1999).
- Seranski P, Hoff C, Radelof U, Hennig S, Reinhardt R, et al: *RAI1* is a novel polyglutamine encoding gene that is deleted in Smith-Magenis syndrome patients. *Gene* 270:69–76 (2001).
- Shaw CJ, Lupski JR: Non-recurrent 17p11.2 deletions are generated by homologous and non-homologous mechanisms. *Hum Genet* 116: 1–7 (2005).
- Slager RE, Newton TL, Vlangos CN, Finucane B, Elsea SH: Mutations in *RAI1* associated with Smith-Magenis syndrome. *Nat Genet* 33: 466–468 (2003).
- Smith AC, McGavran L, Robinson J, Waldstein G, Macfarlane J, et al: Interstitial deletion of (17)(p11.2p11.2) in nine patients. *Am J Med Genet* 24:393–414 (1986).
- Stankiewicz P, Shaw CJ, Dapper JD, Wakui K, Shaffer LG, et al: Genome architecture catalyzes nonrecurrent chromosomal rearrangements. *Am J Hum Genet* 72:1101–1016 (2003).
- Streisinger G, Okada Y, Emrich J, Newton J, Tsugita A, et al: Frameshift mutations and the genetic code. This paper is dedicated to Professor Theodosius Dobzhansky on the occasion of his 66th birthday. *Cold Spring Harb Symp Quant Biol* 31:77–84 (1966).
- Tautz D, Schlötterer C: Simple sequences. *Curr Opin Genet Dev* 4:832–837 (1994).
- Toulouse A, Rochefort D, Roussel J, Joobor R, Rouleau GA: Molecular cloning and characterization of human *RAI1*, a gene associated with schizophrenia. *Genomics* 82:162–171 (2003).
- Trask BJ, Mefford H, van den Engh G, Massa HF, Juyal RC, et al: Quantification by flow cytometry of chromosome-17 deletions in Smith-Magenis syndrome patients. *Hum Genet* 98: 710–718 (1996).
- Truong HT, Dudding T, Blanchard CL, Elsea SH: Frameshift mutation hotspot identified in Smith-Magenis syndrome: case report and review of literature. *BMC Med Genet* 11:142 (2010).
- Vieira GH, Rodriguez JD, Carmona-Mora P, Cao L, Gamba BF, et al: Detection of classical 17p11.2 deletions, an atypical deletion and *RAI1* alterations in patients with features suggestive of Smith-Magenis syndrome. *Eur J Hum Genet* 20:148–154 (2012).
- Vilboux T, Ciccone C, Blancato JK, Cox GF, Deshpande C, et al: Molecular analysis of the *Retinoic Acid Induced 1 Gene (RAI1)* in patients with suspected Smith-Magenis syndrome without the 17p11.2 deletion. *PLoS ONE* 6:e22861 (2011).
- Vlangos CN, Yim DK, Elsea SH: Refinement of the Smith-Magenis syndrome critical region to approximately 950 kb and assessment of 17p11.2 deletions. Are all deletions created equally? *Mol Genet Metab* 79:134–141 (2003).
- Williams SR, Zies D, Mullegama SV, Grotewiel MS, Elsea SH: Smith-Magenis syndrome results in disruption of *CLOCK* gene transcription and reveals an integral role for *RAI1* in the maintenance of circadian rhythmicity. *Am J Hum Genet* 90:941–949 (2012).